📰 ReutersReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 19:08:31时区推断·⟳ 抓取 19:09:31·⚡ 决策 07-29 19:24:45 +15m14s·89.8 天前
波士顿科学下调全年利润和有机增长指引，但二季度业绩好于预期
二季度调整后EPS 0.86美元、收入54.4亿美元均高于LSEG预期，但全年调整后EPS指引从3.34-3.41美元下调至3.28-3.32美元，且有机增长指引从6.5%-8%下调至5%-6%。
📄 原文Reuters↗ 原文
Medical device maker Boston Scientific (BSX.N) on Wednesday lowered its annual profit forecast, citing pressure on its…
不做 波士顿科学（BSX.US）
财报事件正负混合：全年EPS和有机增长下修偏空，但Q2业绩超预期且盘前上涨，Watchman压力也已在5月披露过；当前既不适合追多，也不满足强空催化和借券核验条件。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司5月已在会议上提示Watchman独立手术使用下降、设备需求疲软，BSX当日曾大跌，说明核心负面并非首次出现。市场反应:报道称BSX盘中跌约11.8%至50.83美元。
- 公司披露重组计划，涉及供应链优化、生产转移和组织调整，预计到2029年底大体完成；这是本次财报前的成本重置背景。
- Reuters盘前报道BSX因Watchman需求疲软下调全年EPS和有机增长指引，同时二季度收入和EPS高于预期。市场反应:Reuters称BSX盘前上涨近4%。
关键理由
- 二季度调整后EPS 0.86美元、收入54.4亿美元均高于LSEG预期，但全年调整后EPS指引从3.34-3.41美元下调至3.28-3.32美元，且有机增长指引从6.5%-8%下调至5%-6%。
- Watchman需求疲软不是全新信息，5月公司已提示相关压力，7月本次更多是财报日对全年模型的再次重置。
- 盘前股价反而上涨约4%，说明市场短线更重视业绩超预期和重置完成，无法形成同向做空或做多的清晰正期望。
主要风险
- 若正式电话会进一步下调Watchman恢复节奏或2027增长预期，BSX.US仍可能转为可做空的基本面下修事件。
- 若开盘后高开低走，说明盘前“reset”交易失败，但当前仍缺少借券核验和强空确认。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-04-22 · 影响 weakens
4月同类指引下修后BSX上涨超过8%，且本次盘前亦上涨约4%，削弱直接开空胜率。
检索:Boston Scientific Watchman demand guidance cut shares rise reset April 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-29 · 影响 weakens
全年EPS和有机销售增长指引均低于此前口径及市场预期，限制追多业绩beat的质量。
检索:Boston Scientific trims annual profit forecast softer Watchman demand July 2026 原文 ↗
历史先例(按相似度)
- 相似度 8/10 BSX 2026-04-22 BSX在2026年4月下调全年EPS和有机增长指引，分析师称可能是投资者等待的reset。 原文 ↗
Reuters称BSX当日上涨超过8%，显示指引下修在已预期背景下可能被当作清仓式重置交易。
相似度依据:同一公司、同一年财报日下调全年指引并被市场解读为重置，和当前事件机制接近。 - 相似度 7/10 BSX 2026-05-27 公司在Bernstein会议上提示Watchman独立手术使用下降、需求疲软。 原文 ↗
Reuters称BSX盘中跌约11.8%，说明Watchman压力首次明确暴露时杀伤较大。
相似度依据:同一公司、同一Watchman需求问题，但事件相位是会议提示而非正式财报重置。
原文全文
展开原文 · 1,943 字
Medical device maker Boston Scientific (BSX.N) on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.
The company, in May, warned of pressure on its Watchman heart device, a small implant used to help prevent stroke-causing blood clots in patients with atrial fibrillation, due to softer-than-expected uptake.
Boston Scientific said growth was being weighed down by a decline in standalone Watchman procedures as physicians increasingly combine the implant with other cardiac treatments during a single visit.
As a result, the company said it expects flat Watchman revenue growth in the second and likely third quarter, despite continued uptake in combined procedures.
On Monday, Boston Scientific's board approved a new company-wide restructuring plan aimed at cutting costs and better positioning the company for future growth.
The plan, approved on July 21, includes supply chain optimization, production shifts between manufacturing sites and organizational changes, and is expected to be largely completed by the end of 2029.
Shares of the company were up nearly 4% premarket after it beat second-quarter results.
The Massachusetts-based company posted second-quarter adjusted profit of 86 cents per share, above analysts' estimate of 83 cents per share, according to LSEG data.
Its quarterly revenue came in at $5.44 billion, above analysts' expectations of $5.36 billion.
The company's cardiovascular unit posted quarterly sales of $3.62 billion, beating estimates of $3.58 billion.
Boston Scientific now expects 2026 adjusted profit per share to be between $3.28 and $3.32, compared to its prior view in the range of $3.34 to $3.41 per share. Analysts were expecting annual adjusted profit at $3.36 per share.
The company now expects organic sales growth for 2026 to be between 5% and 6%, compared to its previous expectations in the range of 6.5% to 8%.
The company, in May, warned of pressure on its Watchman heart device, a small implant used to help prevent stroke-causing blood clots in patients with atrial fibrillation, due to softer-than-expected uptake.
Boston Scientific said growth was being weighed down by a decline in standalone Watchman procedures as physicians increasingly combine the implant with other cardiac treatments during a single visit.
As a result, the company said it expects flat Watchman revenue growth in the second and likely third quarter, despite continued uptake in combined procedures.
On Monday, Boston Scientific's board approved a new company-wide restructuring plan aimed at cutting costs and better positioning the company for future growth.
The plan, approved on July 21, includes supply chain optimization, production shifts between manufacturing sites and organizational changes, and is expected to be largely completed by the end of 2029.
Shares of the company were up nearly 4% premarket after it beat second-quarter results.
The Massachusetts-based company posted second-quarter adjusted profit of 86 cents per share, above analysts' estimate of 83 cents per share, according to LSEG data.
Its quarterly revenue came in at $5.44 billion, above analysts' expectations of $5.36 billion.
The company's cardiovascular unit posted quarterly sales of $3.62 billion, beating estimates of $3.58 billion.
Boston Scientific now expects 2026 adjusted profit per share to be between $3.28 and $3.32, compared to its prior view in the range of $3.34 to $3.41 per share. Analysts were expecting annual adjusted profit at $3.36 per share.
The company now expects organic sales growth for 2026 to be between 5% and 6%, compared to its previous expectations in the range of 6.5% to 8%.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。